Company / SG&A Expense
Organon & Co. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$1.7B
FY2025
5-year range
$1.4B / $1.9B
FY2021-FY2025
Trend
-2.2%
vs FY2024
Sector context
#17 of 213
Health Care
What the data says
Among 213 Health Care companies, Organon & Co. is in the bottom 8% for sg&a expense. Improved from $1.9B to $1.7B over the past 2 years.
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of +4.9%. Top quartile in the Health Care sector.
Improved from $1.9B to $1.7B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +0.3%
- 5-Year CAGR
- +4.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 8% in Health CareTop 92% of 213This company $1.7B Sector average $722.3M
▼
+138.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.9%, indicating consistent growth.
- In FY2025, sg&a expense decreased 2.2% year-over-year.
- Ranks #17 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | -2.2% |
| FY2024 | $1.8B | -7.0% |
| FY2023 | $1.9B | +11.1% |
| FY2022 | $1.7B | +18.1% |
| FY2021 | $1.4B | +6.4% |
| FY2020 | $1.4B | -6.0% |
| FY2019 | $1.4B | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026